Evidence map›Paper›PMID 41733039›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Aptamer-Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer.

Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiayi WangInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xuan WangInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xinfeng DaiInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Linxin TianInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wencheng ShenInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xueliang LiuInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wei XueInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jiahua PanInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yu YangInstitute of Molecular Medicine (IMM) and Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0002-4518-3299

Funding

Fundamental Research Funds for the Central Universities 2020JCPT02National Key Research and Development Program of China 2022YFA1206500National Natural Science Foundation of China 22277072National Natural Science Foundation of China 32401161Natural Science foundation of Shanghai, China 24ZR1462700Natural Science foundation of Shanghai, China 25ZR1402322Science and Technology Development Fund of Pudong Health Bureau of Shanghai PKJ2024-Y40Shanghai Oriental Talents QNWS2024055Shuguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission 24SG20
6 · The paper itself

Abstract

Prostate cancer (PCa) is a prototypical "cold tumor" with low immunogenicity and a highly immunosuppressive tumor microenvironment, which severely limits the efficacy of immunotherapy. Notably, the number and functionality of conventional type 1 dendritic cells (cDC1), which are critical antigen-presenting cells, are markedly reduced in PCa, thereby impairing T cell priming. Here, we developed an aptamer-modified liposomal platform (Apt-Flt3L@Lipo) for the targeted co-delivery of Flt3 ligand (Flt3L) and chlorin e6 (Ce6) to elicit in situ cDC1 vaccination. Upon ultrasound activation, Ce6 induced immunogenic cell death (ICD) in tumor cells, releasing abundant tumor antigens, while the concurrently released Flt3L promoted the differentiation and intratumoral recruitment of cDC1s. Thus, by coupling antigen release with cDC1 activation, we generated an in situ cDC1 vaccine, which enhanced antigen cross-presentation, primed CD8

Indexed as

aptamerimmune checkpoint blockade (ICB)in situ cDC1 vaccinationliposomeprostate cancer (PCa)

Identifiers

PMID41733039
PMCPMC13326002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.